title: Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma.
authors.affiliation: Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ, USA.
authors.forename: Chang-Xin
authors.initials: CX
authors.lastname: Shi
authors.affiliation: Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ, USA.
authors.forename: Klaus Martin
authors.initials: KM
authors.lastname: Kortüm
authors.affiliation: Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ, USA.
authors.forename: Yuan Xiao
authors.initials: YX
authors.lastname: Zhu
authors.affiliation: Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ, USA.
authors.forename: Patrick
authors.initials: P
authors.lastname: Jedlowski
authors.affiliation: Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ, USA.
authors.forename: Laura
authors.initials: L
authors.lastname: Bruins
authors.affiliation: Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ, USA.
authors.forename: Esteban
authors.initials: E
authors.lastname: Braggio
authors.affiliation: Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ, USA stewart.keith@mayo.edu.
authors.forename: A Keith
authors.initials: AK
authors.lastname: Stewart
mesh_terms: D006801:Humans; D051740:Ikaros Transcription Factor / Q000378:metabolism*; D007155:Immunologic Factors / Q000494:pharmacology*; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000235:genetics / Q000378:metabolism*; D061988:Proteasome Inhibitors / Q000494:pharmacology*; D059748:Proteolysis / Q000187:drug effects; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D007155:Immunologic Factors; D061988:Proteasome Inhibitors; D051740:Ikaros Transcription Factor; D013792:Thalidomide; D000077269:Lenalidomide
keywords: IKZF1 depletion; IMiDs; myeloma